```
=> d his

     (FILE 'HOME' ENTERED AT 10:50:52 ON 05 JAN 2005)

     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 10:52:20 ON
     05 JAN 2005
                E MASH D/CN
                E MASH DEBORAH/CN
                E MASH DEBORAH/AU
L1          179 S E3-E5
L2          119 DUP REM L1 (60 DUPLICATES REMOVED)
L3           21 S L2 AND (IBOGAINE OR NORIBOGAINE)
L4            1 S L3 AND (PAIN OR MIGRAIN? OR HEADACHE OR ANALGE?)

     FILE 'FRFULL, PATDPAFULL, PCTFULL, RDISCLOSURE, USPATFULL, USPAT2'
     ENTERED AT 11:00:03 ON 05 JAN 2005
                E MASH DEBORAH/IN
L5            7 S E4-E5
L6            7 DUP REM L5 (0 DUPLICATES REMOVED)
L7            6 S L6 AND (IBOGAINE OR NORIBOGAINE)
L8            6 S L7 AND (PAIN OR MIGRAIN? OR HEADACHE OR ANALGE?)

     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH' ENTERED AT 11:09:01 ON
     05 JAN 2005
```

X not in absence of an opioid analg

=> s l7 and (PAIN OR MIGRAIN? OR HEADACHE OR ANALGE?)
L8 6 L7 AND (PAIN OR MIGRAIN? OR HEADACHE OR ANALGE?)

=> d ibib 1-6

L8 ANSWER 1 OF 6 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1999011250 PCTFULL ED 20020515
TITLE (ENGLISH): **NORIBOGAINE** IN THE TREATMENT OF **PAIN** AND DRUG ADDICTION
TITLE (FRENCH): **NORIBOGAINE** UTILISEE POUR LE TRAITEMENT DE LA DOULEUR ET DE LA TOXICOMANIE
INVENTOR(S): **MASH, Deborah, C.**
PATENT ASSIGNEE(S): NOVONEURON, INC.;
MASH, Deborah, C.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9911250	A2	19990311

same invention in PCT

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 1998-US18284 A 19980903
PRIORITY INFO.: US 1997-60/057,921 19970904

L8 ANSWER 2 OF 6 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1997020847 PCTFULL ED 20020514
TITLE (ENGLISH): TRICYCLIC **IBOGAINE** ANALOGS, THEIR PREPARATION AND THEIR USE IN TREATING SUBSTANCE ABUSE
TITLE (FRENCH): ANALOGUES D'**IBOGAINE** TRICYCLIQUES, LEUR PREPARATION ET LEUR UTILISATION POUR TRAITER LA TOXICOMANIE
INVENTOR(S): EFANGE, S., Mbua, Ngale;
MASH, Deborah, Carmen
PATENT ASSIGNEE(S): REGENTS OF THE UNIVERSITY OF MINNESOTA;
UNIVERSITY OF MIAMI
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9720847	A1	19970612

DESIGNATED STATES
W: CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1996-US17868 A 19961106
PRIORITY INFO.: US 1995-8/567,374 19951204

L8 ANSWER 3 OF 6 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1996003127 PCTFULL ED 20020514
TITLE (ENGLISH): A METHOD OF TREATING CHEMICAL DEPENDENCY IN MAMMALS AND A COMPOSITION THEREFOR
TITLE (FRENCH): PROCEDE ET COMPOSITION DE TRAITEMENT DE LA DEPENDANCE CHIMIQUE CHEZ LES MAMMIFERES
INVENTOR(S): **MASH, Deborah, C.**;
SANCHEZ-RAMOS, Juan;
HEARN, W., Lee
PATENT ASSIGNEE(S): NDA INTERNATIONAL, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

	WO 9603127 A1 19960208
DESIGNATED STATES W:	CA MX AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.:	WO 1995-US9136 A 19950725
PRIORITY INFO.:	US 1994-280,187 19940725

L8 ANSWER 4 OF 6 USPATFULL on STN

ACCESSION NUMBER:	2003:220261 USPATFULL
TITLE:	Method of treating chemical dependency in mammals and a composition therefor
INVENTOR(S):	**Mash, Deborah C.**, North Bay Village, FL, UNITED STATES Sanchez-Ramos, Juan, Tampa, FL, UNITED STATES Hearn, William Lee, Miami Springs, FL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003153552	A1	20030814	
APPLICATION INFO.:	US 2002-75915	A1	20020214	(10)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	MALIN HALEY AND DIMAGGIO, PA, 1936 S ANDREWS AVENUE, FORT LAUDERDALE, FL, 33316			
NUMBER OF CLAIMS:	18			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	1 Drawing Page(s)			
LINE COUNT:	386			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 6 USPATFULL on STN

ACCESSION NUMBER:	2002:34429 USPATFULL
TITLE:	Method of treating chemical dependency in mammals and a composition therefor
INVENTOR(S):	**Mash, Deborah C.**, 1501 NW. 9th Ave., Miami, FL, United States 33136 Sanchez-Ramos, Juan, 1501 NW. 9th Ave., Miami, FL, United States 33136 Hearn, W. Lee, 1 Bob Hope Rd., Miami, FL, United States 33136-1133

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6348456	B1	20020219	
APPLICATION INFO.:	US 1996-727123		19961008	(8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-280187, filed on 25 Jul 1994, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Shah, Mukund J.			
ASSISTANT EXAMINER:	Truong, Tamthom N.			
LEGAL REPRESENTATIVE:	Malin, Haley & DiMaggio, P.A.			
NUMBER OF CLAIMS:	18			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)			
LINE COUNT:	387			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 6 USPATFULL on STN

ACCESSION NUMBER:	97:27162 USPATFULL
TITLE:	Bioactive tricyclic **ibogaine** analogs
INVENTOR(S):	Efange, S. Mbua N., Plymouth, MN, United States **Mash, Deborah C.**, North Bay Village, FL, United States
PATENT ASSIGNEE(S):	Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation) University of Miami, Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5616575		19970401	
APPLICATION INFO.:	US 1995-567374		19951204	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Reamer, James H.			
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.			
NUMBER OF CLAIMS:	21			
EXEMPLARY CLAIM:	1,17			
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 3 Drawing Page(s)			
LINE COUNT:	671			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l2 and (ibogaine or noribogaine)
L3 21 L2 AND (IBOGAINE OR NORIBOGAINE)

=> d ibib 1-21

L3 ANSWER 1 OF 21 MEDLINE on STN
ACCESSION NUMBER: 2003102212 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12614886
TITLE: **Ibogaine** analogues. Synthesis and preliminary pharmacological evaluation of 7-heteroaryl-2-azabicyclo[2.2.2]oct-7-enes.
AUTHOR: Passarella Daniele; Favia Raffaele; Giardini Alessandra; Lesma Giordano; Martinelli Marisa; Silvani Alessandra; Danieli Bruno; Efange Simon M N; **Mash Deborah C**
CORPORATE SOURCE: Dipartimento di Chimica Organica e Industriale, Universita degli Studi di Milano, Via Venezian 21, 20133 Milan, Italy.. daniele.passarella@unimi.it
SOURCE: Bioorganic & medicinal chemistry, (2003 Mar 20) 11 (6) 1007-14.
Journal code: 9413298. ISSN: 0968-0896.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200311
ENTRY DATE: Entered STN: 20030305
Last Updated on STN: 20031217
Entered Medline: 20031124

L3 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:633279 CAPLUS
DOCUMENT NUMBER: 139:159976
TITLE: Composition and method using a **noribogaine** compound for treating chemical dependency in mammals
INVENTOR(S): **Mash, Deborah C.**; Sanchez-Ramos, Juan; Hearn, William Lee
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003153552	A1	20030814	US 2002-75915	20020214
PRIORITY APPLN. INFO.:			US 2002-75915	20020214

OTHER SOURCE(S): MARPAT 139:159976

L3 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:757619 CAPLUS
DOCUMENT NUMBER: 136:111976
TITLE: **Ibogaine** in the treatment of heroin withdrawal
AUTHOR(S): **Mash, Deborah C.**; Kovera, Craig A.; Pablo, John; Tyndale, Rachel; Ervin, Frank R.; Kamlet, Jeffrey D.; Hearn, W. Lee
CORPORATE SOURCE: Departments of Neurology and Pharmacology, University of Miami School of Medicine, Miami, FL, 33124, USA
SOURCE: Alkaloids (Academic Press) (2001), 56(Ibogaine), 155-171
CODEN: ALKAAR; ISSN: 0099-9598
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:757617 CAPLUS
DOCUMENT NUMBER: 136:111974
TITLE: Comparative neuropharmacology of **ibogaine** and its O-desmethyl metabolite, **noribogaine**
AUTHOR(S): Baumann, Michael H.; Pablo, John; Ali, Syed F.; Rothman, Richard B.; **Mash, Deborah C.**
CORPORATE SOURCE: Clinical Psychopharmacology Section Intramural Research Program National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, 21224, USA
SOURCE: Alkaloids (Academic Press) (2001), 56(Ibogaine), 79-113
CODEN: ALKAAR; ISSN: 0099-9598
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 152 THERE ARE 152 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:321619 CAPLUS
DOCUMENT NUMBER: 135:132300
TITLE: In vivo neurobiological effects of **ibogaine** and its O-desmethyl metabolite, 12-hydroxyibogamine (**noribogaine**), in rats
AUTHOR(S): Baumann, Michael H.; Rothman, Richard B.; Pablo, John P.; **Mash, Deborah C.**
CORPORATE SOURCE: Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2001), 297(2), 531-539
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:842753 CAPLUS
DOCUMENT NUMBER: 134:360947
TITLE: **Ibogaine**: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures
AUTHOR(S): **Mash, Deborah C.**; Kovera, Craig A.; Pablo, John; Tyndale, Rachel F.; Ervin, Frank D.; Williams, Izben C.; Singleton, Edward G.; Mayor, Manny
CORPORATE SOURCE: Department of Neurology, University of Miami School of Medicine, Miami, FL, 33136, USA
SOURCE: Annals of the New York Academy of Sciences (2000), 914(Neurobiological Mechanisms of Drugs of Abuse), 394-401
CODEN: ANYAA9; ISSN: 0077-8923
PUBLISHER: New York Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:410216 CAPLUS
DOCUMENT NUMBER: 131:167751
TITLE: Indole alkaloids from tissue-cultured Tabernanthe

iboga

AUTHOR(S): Basile, Dominick V.; Punch, Michell S.; Pablo, John; Brenner, Bruce; Hearn, W. Lee; **Mash, Deborah C.**

CORPORATE SOURCE: Department Biological Sciences, Lehman College, CUNY, New York, NY, 10468, USA

SOURCE: Natural Product Letters (1999), 13(3), 233-238
CODEN: NPLEEF; ISSN: 1057-5634

PUBLISHER: Harwood Academic Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:184122 CAPLUS

DOCUMENT NUMBER: 130:205166

TITLE: **Noribogaine** in the treatment of pain and drug addiction

INVENTOR(S): **Mash, Deborah C.**

PATENT ASSIGNEE(S): Novoneuron, Inc., USA

SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911250	A2	19990311	WO 1998-US18284	19980903
WO 9911250	A3	19990805		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2302754	AA	19990311	CA 1998-2302754	19980903
AU 9892174	A1	19990322	AU 1998-92174	19980903
AU 754088	B2	20021107		
EP 1009407	A2	20000621	EP 1998-944698	19980903
EP 1009407	B1	20040428		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
EP 1327447	A1	20030716	EP 2003-75683	19980903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
AT 265213	E	20040515	AT 1998-944698	19980903

PRIORITY APPLN. INFO.:

US 1997-57921P	P	19970904
EP 1998-944698	A3	19980903
WO 1998-US18284	W	19980903

L3 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:622200 CAPLUS

DOCUMENT NUMBER: 129:343618

TITLE: Modified **Ibogaine** Fragments: Synthesis and Preliminary Pharmacological Characterization of 3-Ethyl-5-phenyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]benzothiophenes

AUTHOR(S): Efange, Simon M. N.; **Mash, Deborah C.**; Khare, Anil B.; Ouyang, Quinjie

CORPORATE SOURCE: Departments of Radiology Medicinal Chemistry and Neurosurgery, Graduate Program in Neuroscience University of Minnesota, Minneapolis, MN, 55455, USA

SOURCE: Journal of Medicinal Chemistry (1998), 41(23), 4486-4491
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129:343618
REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:540906 CAPLUS
DOCUMENT NUMBER: 129:225279
TITLE: Cytochrome P 450 2D6 catalyzes the O-demethylation of the psychoactive alkaloid **ibogaine** to 12-hydroxyibogamine
AUTHOR(S): Obach, R. Scott; Pablo, John; **Mash, Deborah C.**
CORPORATE SOURCE: Central Research Division, Department of Drug Metabolism, Groton, CT, 06340, USA
SOURCE: Drug Metabolism and Disposition (1998), 26(8), 764-768
CODEN: DMDSAI; ISSN: 0090-9556
PUBLISHER: Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:469623 CAPLUS
DOCUMENT NUMBER: 129:170461
TITLE: Medication development of **ibogaine** as a pharmacotherapy for drug dependence
AUTHOR(S): **Mash, Deborah C.**; Kovera, Craig A.; Buck, Billy E.; Norenberg, Michael D.; Shapshak, Paul; Hearn, W. Lee; Sanchez-Ramos, Juan
CORPORATE SOURCE: Departments of Neurology, Psychiatry, Orthopedics, and Pathology, University of Miami School of Medicine, Miami, FL, 33136, USA
SOURCE: Annals of the New York Academy of Sciences (1998), 844(Neurochemistry of Drugs of Abuse), 274-292
CODEN: ANYAA9; ISSN: 0077-8923
PUBLISHER: New York Academy of Sciences
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:108539 CAPLUS
DOCUMENT NUMBER: 128:200970
TITLE: **Noribogaine** stimulates naloxone-sensitive [35S]GTPγS binding
AUTHOR(S): Pablo, John P.; **Mash, Deborah C.**
CORPORATE SOURCE: Departments of Neurology (D4-5) and Molecular and Cellular Pharmacology, University of Miami School of Medicine, Miami, FL, USA
SOURCE: NeuroReport (1998), 9(1), 109-114
CODEN: NERPEZ; ISSN: 0959-4965
PUBLISHER: Rapid Science Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:231457 CAPLUS
DOCUMENT NUMBER: 126:277643
TITLE: Preparation of tricyclic **ibogaine** analogs for treating cocaine addiction
INVENTOR(S): Efange, S. Mbua N.; **Mash, Deborah C.**
PATENT ASSIGNEE(S): Regents of the University of Minnesota, USA;

SOURCE: University of Miami
U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5616575	A	19970401	US 1995-567374	19951204
CA 2238524	AA	19970612	CA 1996-2238524	19961106
WO 9720847	A1	19970612	WO 1996-US17868	19961106
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 910567	A1	19990428	EP 1996-940321	19961106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000501702	T2	20000215	JP 1997-521270	19961106
PRIORITY APPLN. INFO.:			US 1995-567374 A	19951204
			WO 1996-US17868 W	19961106

OTHER SOURCE(S): MARPAT 126:277643

L3 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:572474 CAPLUS
DOCUMENT NUMBER: 125:238572
TITLE: Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid **ibogaine**
AUTHOR(S): Staley, Julie K.; Ouyang, Qinjie; Pablo, John; Hearn, W. Lee; Flynn, Donna D.; Rothman, Richard B.; Rice, Kenner C.; **Mash, Deborah C.**
CORPORATE SOURCE: Dep. Neurol., Univ. Miami Sch. Med., Miami, FL, 33101, USA
SOURCE: Psychopharmacology (Berlin) (1996), 127(1), 10-18
CODEN: PSCHDL; ISSN: 0033-3158
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

L3 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:321083 CAPLUS
DOCUMENT NUMBER: 124:333123
TITLE: **Noribogaine** compounds for treating chemical dependency in mammals
INVENTOR(S): **Mash, Deborah C.**; Sanchez-Ramos, Juan; Hearn, W. Lee
PATENT ASSIGNEE(S): Nda International, Inc., USA
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9603127	A1	19960208	WO 1995-US9136	19950725
W: CA, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9646132	A1	19960419	AU 1996-46132	19950725
EP 804200	A1	19971105	EP 1995-927295	19950725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
IL 114726	A1	20020421	IL 1995-114726	19950725
US 6348456	B1	20020219	US 1996-727123	19961008
PRIORITY APPLN. INFO.:			US 1994-280187 A	19940725
			WO 1995-US9136 W	19950725

OTHER SOURCE(S): MARPAT 124:333123

L3 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:850984 CAPLUS
DOCUMENT NUMBER: 123:275065
TITLE: Identification and quantification of **ibogaine** and an o-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry
AUTHOR(S): Hearn, William L.; Pablo, John; Hime, George W.; **Mash, Deborah C.**
CORPORATE SOURCE: Metro-Dade County Medical Examiner's Dep., Univ. of Miami School of Medicine, Miami, FL, 33136, USA
SOURCE: Journal of Analytical Toxicology (1995), 19(6), 427-34
CODEN: JATOD3; ISSN: 0146-4760
PUBLISHER: Preston Publications
DOCUMENT TYPE: Journal
LANGUAGE: English

L3 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:621179 CAPLUS
DOCUMENT NUMBER: 123:47718
TITLE: Identification of a primary metabolite of **ibogaine** that targets serotonin transporters and elevates serotonin
AUTHOR(S): **Mash, Deborah C.**; Staley, Julie K.; Baumann, Michael H.; Rothman, Richard B.; Hearn, W. Lee
CORPORATE SOURCE: Dep. Neurology, Univ. Miami School Medicine, Miami, FL, 33136, USA
SOURCE: Life Sciences (1995), 57(3), PL45-PL50
CODEN: LIFSAK; ISSN: 0024-3205
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

L3 ANSWER 18 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
ACCESSION NUMBER: 2002:197986 BIOSIS
DOCUMENT NUMBER: PREV200200197986
TITLE: Method of treating chemical dependency in mammals and a composition therefor.
AUTHOR(S): **Mash, Deborah C.** [Inventor, Reprint author]; Sanchez-Ramos, Juan [Inventor]; Hearn, W. Lee [Inventor]
CORPORATE SOURCE: 1501 NW. 9th Ave., Miami, FL, 33136, USA
PATENT INFORMATION: US 6348456 February 19, 2002
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Feb. 19, 2002) Vol. 1255, No. 3. http://www.uspto.gov/web/menu/patdata.html. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 13 Mar 2002
Last Updated on STN: 13 Mar 2002

L3 ANSWER 19 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
ACCESSION NUMBER: 2001:205680 BIOSIS
DOCUMENT NUMBER: PREV200100205680
TITLE: **Ibogaine**: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.
AUTHOR(S): **Mash, Deborah C.** [Reprint author]; Kovera, Craig A.; Pablo, John; Tyndale, Rachel F.; Ervin, Frank D.; Williams, Izben C.; Singleton, Edward G.; Mayor, Manny
CORPORATE SOURCE: Department of Neurology (D4-5), 1501 N. W. 9th Avenue, Miami, FL, USA
dmash@med.miami.edu
SOURCE: Ali, Syed F. Ann. N. Y. Acad. Sci., (2000) pp. 394-401. Annals of the New York Academy of Sciences. Neurobiological mechanisms of drugs and abuse: Cocaine, ibogaine, and

substituted amphetamines. print.
Publisher: New York Academy of Sciences, 2 East 63rd Street, New York, NY, 10021, USA. Series: Annals of the New York Academy of Sciences.
Meeting Info.: Conference on Cellular and Molecular Mechanisms of Drugs of Abuse: Cocaine, Ibogaine and Substituted Amphetamines held at a Satellite Meeting of the International Society for Neurochemistry and the European Society for Neurochemistry. Copenhagen, Denmark. August 04-06, 1999.
CODEN: ANYAA9. ISSN: 0077-8923. ISBN: 1-57331-279-7 (cloth), 1-57331-280-0 (paper).

DOCUMENT TYPE: Book
Conference; (Meeting)
Book; (Book Chapter)
Conference; (Meeting Paper)

LANGUAGE: English

ENTRY DATE: Entered STN: 25 Apr 2001
Last Updated on STN: 19 Feb 2002

L3 ANSWER 20 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN

ACCESSION NUMBER: 1998:383618 BIOSIS

DOCUMENT NUMBER: PREV199800383618

TITLE: Medication development of **ibogaine** as a pharmacotherapy for drug dependence.

AUTHOR(S): **Mash, Deborah C.**; Kovera, Craig A.; Buck, Billy E.; Norenberg, Michael D.; Shapshak, Paul; Hearn, W. Lee; Sanchez-Ramos, Juan

CORPORATE SOURCE: Dep. Neurol., 1501 N.W. 9th Ave., Miami, FL 33136, USA

SOURCE: Ali, S. F. [Editor]. Ann. N. Y. Acad. Sci., (1998) pp. 274-292. Annals of the New York Academy of Sciences; The neurochemistry of drugs of abuse; Cocaine, ibogaine, and substituted amphetamines. print.
Publisher: New York Academy of Sciences, 2 East 63rd Street, New York, New York 10021, USA. Series: Annals of the New York Academy of Sciences.
Meeting Info.: Satellite Meeting of the International Society for Neurochemistry and the American Society for Neurochemistry. Hamilton, Bermuda. July 16-18, 1997. American Society for Neurochemistry; International Society for Neurochemistry.
CODEN: ANYAA9. ISSN: 0077-8923. ISBN: 1-57331-145-6 (cloth), 1-57331-146-4 (paper).

DOCUMENT TYPE: Book
Conference; (Meeting)
Book; (Book Chapter)
Conference; (Meeting Paper)

LANGUAGE: English

ENTRY DATE: Entered STN: 2 Sep 1998
Last Updated on STN: 2 Sep 1998

L3 ANSWER 21 OF 21 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN

ACCESSION NUMBER: 1996:142587 BIOSIS

DOCUMENT NUMBER: PREV199698714722

TITLE: Neuropsychiatric effects of **ibogaine** in drug dependent patients.

AUTHOR(S): Douyon, Richard; Levin, Bonnie; Hearn, W. Lee; Sanchez-Ramos, Juan; **Mash, Deborah C.**

CORPORATE SOURCE: Univ. Miami Sch. Med., Miami, FL, USA

SOURCE: Psychopharmacology Bulletin, (1995) Vol. 31, No. 3, pp. 561.
Meeting Info.: New Clinical Drug Evaluation Unit Meeting. May-June 1995.
CODEN: PSYBB9. ISSN: 0048-5764.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 3 Apr 1996
Last Updated on STN: 26 Apr 1996

L3 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:850984 CAPLUS
DOCUMENT NUMBER: 123:275065
TITLE: Identification and quantification of **ibogaine** and an o-demethylated metabolite in brain and biological fluids using gas chromatography-mass spectrometry
AUTHOR(S): Hearn, William L.; Pablo, John; Hime, George W.; **Mash, Deborah C.**
CORPORATE SOURCE: Metro-Dade County Medical Examiner's Dep., Univ. of Miami School of Medicine, Miami, FL, 33136, USA
SOURCE: Journal of Analytical Toxicology (1995), 19(6), 427-34
CODEN: JATOD3; ISSN: 0146-4760
PUBLISHER: Preston Publications
DOCUMENT TYPE: Journal
LANGUAGE: English

AB This report describes a sensitive method for quantitating **ibogaine** and a single major metabolite in biol. fluids and brain tissue. We identified the metabolite as 12-hydroxy-ibogamine (12-OH-ibogamine or **noribogaine**) by full-scan, electron-impact gas chromatog.-mass spectrometry (GC-MS). **Ibogaine**, 12-OH-ibogamine, and o-(methyl)-**ibogaine**-d3 (**ibogaine**-d3) internal standard were isolated by solvent extraction under basic conditions. The resulting organic extract was evaporated to dryness, and the residue was derivatized at room temperature with Et iodide in the presence of tri-Me anilinium hydroxide in DMSO. The reaction was terminated by acidification and washed with organic solvents to remove impurities. The aqueous phase was then alkalinized and reextd. The organic extract was concentrated and analyzed by GC-MS. Quantitation was based upon the ratios of the mol. ions at m/z 310 for **ibogaine**, m/z 313 for **ibogaine**-d3, and m/z 324 for 12-OH-ibogamine Et ether. The limit of detection was 5 ng/mL for both **ibogaine** and derivatized 12-OH-ibogamine, and limits of quantitation were between 5 and 10 ng/mL for all matrixes tested. Calibration curves were linear in the range of 5-1000 ng/mL or ng/g for both analytes.

```
=> d his

     (FILE 'HOME' ENTERED AT 14:06:12 ON 04 JAN 2005)

     FILE 'REGISTRY' ENTERED AT 14:07:02 ON 04 JAN 2005
               E IBOGAINE/CN
L1             1 S E3

     FILE 'CAPLUS' ENTERED AT 14:14:38 ON 04 JAN 2005
L2           454 S L1 OR NSC(W)249764 OR ?IBOGAINE OR IBOGAIN
L3            15 S L2(L)(PAIN OR MIGRAINE OR HEADACHE OR ANALGE?)
     FILE 'FRFULL, PATDPAFULL, PCTFULL, RDISCLOSURE, USPATFULL, USPAT2'
     ENTERED AT 14:48:31 ON 04 JAN 2005
L4            97 S L3
```

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 83-74-9 REGISTRY

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN Ibogamine, 12-methoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 6,9-Methano-5H-pyrido[1',2':1,2]azepino[4,5-b]indole, ibogamine deriv.
CN **Ibogaine (7CI, 8CI)**
OTHER NAMES:
CN (-)-Ibogaine
CN Ibogain
CN NSC 249764

```
=> s e4
L1             1 NORIBOGAINE/CN

=> d rn str cn

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   481-88-9  REGISTRY

Absolute stereochemistry.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

CN   Ibogamin-12-ol (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   6,9-Methano-5H-pyrido[1',2':1,2]azepino[4,5-b]indole, ibogamin-12-ol
     deriv.
CN   Ibogaine, O-demethyl- (6CI, 7CI, 8CI)
OTHER NAMES:
CN   12-Hydroxyibogamine
CN   Noribogaine
CN   O-Demethylibogaine
CN   O-Noribogaine
```

L4 ANSWER 30 OF 97 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1997029735 PCTFULL ED 20020514
TITLE (ENGLISH): DERMAL PENETRATION ENHANCERS AND DRUG DELIVERY SYSTEMS INVOLVING SAME
TITLE (FRENCH): PROMOTEURS DE PENETRATION DERMIQUE ET SYSTEME D'ADMINISTRATION DE MEDICAMENTS COMPRENANT CES PROMOTEURS
INVENTOR(S): REED, Barry, Leonard;
MORGAN, Timothy, Matthias;
FINNIN, Barrie, Charles
PATENT ASSIGNEE(S): MONASH UNIVERSITY;
REED, Barry, Leonard;
MORGAN, Timothy, Matthias;
FINNIN, Barrie, Charles
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9729735	A1	19970821

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.: WO 1997-AU91 A 19970219
PRIORITY INFO.: AU 1996-PN 8144 19960219

L4 ANSWER 31 OF 97 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1997020847 PCTFULL ED 20020514
TITLE (ENGLISH): TRICYCLIC **IBOGAINE** ANALOGS, THEIR PREPARATION AND THEIR USE IN TREATING SUBSTANCE ABUSE
TITLE (FRENCH): ANALOGUES D'**IBOGAINE** TRICYCLIQUES, LEUR PREPARATION ET LEUR UTILISATION POUR TRAITER LA TOXICOMANIE
INVENTOR(S): EFANGE, S., Mbua, Ngale;
MASH, Deborah, Carmen
PATENT ASSIGNEE(S): REGENTS OF THE UNIVERSITY OF MINNESOTA;
UNIVERSITY OF MIAMI
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9720847	A1	19970612

DESIGNATED STATES
W: CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1996-US17868 A 19961106
PRIORITY INFO.: US 1995-8/567,374 19951204

L4 ANSWER 32 OF 97 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1996003127 PCTFULL ED 20020514
TITLE (ENGLISH): A METHOD OF TREATING CHEMICAL DEPENDENCY IN MAMMALS AND A COMPOSITION THEREFOR
TITLE (FRENCH): PROCEDE ET COMPOSITION DE TRAITEMENT DE LA DEPENDANCE CHIMIQUE CHEZ LES MAMMIFERES
INVENTOR(S): MASH, Deborah, C.;
SANCHEZ-RAMOS, Juan;
HEARN, W., Lee
PATENT ASSIGNEE(S): NDA INTERNATIONAL, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9603127	A1	19960208

DESIGNATED STATES
W: CA MX AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1995-US9136 A 19950725
PRIORITY INFO.: US 1994-280,187 19940725

L4 ANSWER 33 OF 97 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1991018609 PCTFULL ED 20020513
TITLE (ENGLISH): A RAPID METHOD FOR INTERRUPTING OR ATTENUATING POLY-DRUG DEPENDENCY SYNDROMES
TITLE (FRENCH): PROCEDE RAPIDE D'INTERRUPTION OU D'ATTENUATION DES SYNDROMES DE DEPENDANCE POLYDROGUES
INVENTOR(S): LOTSOF, Howard, S.
PATENT ASSIGNEE(S): NDA INTERNATIONAL, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9118609	A1	19911212

DESIGNATED STATES
W: AT BE CA CH DE DK ES FR GB GR IT JP LU NL SE
APPLICATION INFO.: WO 1991-US3781 A 19910530
PRIORITY INFO.: US 1990-531,100 19900531

L4 ANSWER 34 OF 97 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1985002115 PCTFULL ED 20020507
TITLE (ENGLISH): A RAPID METHOD FOR INTERRUPTING THE NARCOTIC ADDICTION SYNDROME
TITLE (FRENCH): METHODE RAPIDE PERMETTANT D'INTERROMPRE LE SYNDROME D'ACCOUTUMANCE AUX NARCOTIQUES
INVENTOR(S): LOTSOF, Howard, S.
PATENT ASSIGNEE(S): LOTSOF, Howard, S.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 8502115	A1	19850523

DESIGNATED STATES
W: AT AU BE CF CG CH CM DE DK FI FR GA GB JP LU ML MR NL SE SN TD TG
APPLICATION INFO.: WO 1984-US1851 A 19841113
PRIORITY INFO.: US 1983-553,138 19831118

L4 ANSWER 78 OF 97 USPATFULL on STN
ACCESSION NUMBER: 1999:117490 USPATFULL
TITLE: Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
INVENTOR(S): Olney, John W., Ladue, MO, United States
Farber, Nuri B., University City, MO, United States
PATENT ASSIGNEE(S): Washington University, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5958919		19990928	
APPLICATION INFO.:	US 1996-710727		19960920	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spivack, Phyllis G.
LEGAL REPRESENTATIVE: Kelly, Patrick D.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 3890
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 79 OF 97 USPATFULL on STN
ACCESSION NUMBER: 1999:81826 USPATFULL
TITLE: Use of **ibogaine** for treating neuropathic **pain**
INVENTOR(S): Olney, John W., Ladue, MO, United States
PATENT ASSIGNEE(S): Washington University, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5925634		19990720	
APPLICATION INFO.:	~~US 1997-854979~~		19970513	(8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-398731, filed on 6 Mar 1995, now patented, Pat. No. US 5629307, issued on 13 May 1997 which is a continuation-in-part of Ser. No. US 1992-877839, filed on 1 May 1992 which is a continuation-in-part of Ser. No. US 1990-467139, filed on 18 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-424548, filed on 20 Oct 1989, now patented, Pat. No. US 5034400
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Kelly, Patrick D.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1254
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 80 OF 97 USPATFULL on STN
ACCESSION NUMBER: 1999:56487 USPATFULL
TITLE: Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
INVENTOR(S): Olney, John W., Ladue, MO, United States
Farber, Nuri B., University City, MO, United States
PATENT ASSIGNEE(S): Washington University, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5902815		19990511	
APPLICATION INFO.:	US 1996-709222		19960903	(8)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: MacMillan, Keith D.
LEGAL REPRESENTATIVE: Kelly, Patrick D.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 2014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 81 OF 97 USPATFULL on STN
ACCESSION NUMBER: 1999:27632 USPATFULL
TITLE: Preventing neuronal degeneration in Alzheimer's disease
INVENTOR(S): Olney, John W., Ladue, MO, United States
Farber, Nuri B., University City, MO, United States
PATENT ASSIGNEE(S): Washington University, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5877173		19990302	
APPLICATION INFO.:	US 1996-704093		19960828	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spivack, Phyllis G.
LEGAL REPRESENTATIVE: Kelly, Patrick D.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 3475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 82 OF 97 USPATFULL on STN
ACCESSION NUMBER: 1998:98932 USPATFULL
TITLE: DHA-pharmaceutical agent conjugates of taxanes
INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5795909		19980818	
APPLICATION INFO.:	US 1996-651312		19960522	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jarvis, William R. A.
LEGAL REPRESENTATIVE: Wolf, Greenfield & Sacks, P.C.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 2451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 83 OF 97 USPATFULL on STN
ACCESSION NUMBER: 1998:69048 USPATFULL
TITLE: Use of kainic acid antagonists to prevent toxic side effects of NMDA antagonists
INVENTOR(S): Olney, John W., 1 Lorenzo La., St. Louis, MO, United States 63124

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5767130		19980616	
APPLICATION INFO.:	US 1995-407068		19950320	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-877839, filed on 1 May 1992 which is a continuation-in-part of Ser.

No. US 1990-467139, filed on 18 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-424548, filed on 20 Oct 1989, now patented, Pat. No. US 5034400

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Kelly, Patrick D.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1795
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 84 OF 97 USPATFULL on STN
ACCESSION NUMBER: 97:40786 USPATFULL
TITLE: Use of ibogaine in reducing excitotoxic brain damage
INVENTOR(S): Olney, John W., 1 Lorenzo La., St. Louis, MO, United States 63124

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5629307		19970513
APPLICATION INFO.:	US 1995-398731		19950306 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-877839, filed on 1 May 1992 which is a continuation-in-part of Ser. No. US 1990-467139, filed on 18 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-424548, filed on 20 Oct 1989, now patented, Pat. No. US 5034400

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Kelly, Patrick D.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 85 OF 97 USPATFULL on STN
ACCESSION NUMBER: 97:27162 USPATFULL
TITLE: Bioactive tricyclic ibogaine analogs
INVENTOR(S): Efange, S. Mbua N., Plymouth, MN, United States
Mash, Deborah C., North Bay Village, FL, United States
PATENT ASSIGNEE(S): Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation)
University of Miami, Miami, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5616575		19970401
APPLICATION INFO.:	US 1995-567374		19951204 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Reamer, James H.
LEGAL REPRESENTATIVE: Schwegman, Lundberg, Woessner & Kluth, P.A.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1,17
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 671
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 86 OF 97 USPATFULL on STN
ACCESSION NUMBER: 97:16066 USPATFULL
TITLE: Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)

INVENTOR(S): Olney, John W., Ladue, MO, United States
Farber, Nuri B., University City, MO, United States
PATENT ASSIGNEE(S): Washington University, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5605911		19970225
APPLICATION INFO.:	US 1995-381334		19950131 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Kelly, Patrick D.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1935
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 87 OF 97 USPATFULL on STN
ACCESSION NUMBER: 92:82575 USPATFULL
TITLE: Rapid method for interrupting or attenuating poly-drug dependency syndromes
INVENTOR(S): Lotsof, Howard S., 46 Oxford Pl., Staten Island, NY, United States 10301

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5152994		19921006
APPLICATION INFO.:	US 1990-531100		19900531 (7)

DISCLAIMER DATE: 20020212
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Azpuru, Carlos
LEGAL REPRESENTATIVE: Miskin, Howard C.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 88 OF 97 USPATFULL on STN
ACCESSION NUMBER: 91:50468 USPATFULL
TITLE: Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome
INVENTOR(S): Lotsof, Howard S., Staten Island, NY, United States
PATENT ASSIGNEE(S): NDA International, Inc., Staten Island, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5026697		19910625
APPLICATION INFO.:	US 1990-530263		19900530 (7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Friedman, Stanley J.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 234
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 89 OF 97 USPATFULL on STN
ACCESSION NUMBER: 89:67469 USPATFULL
TITLE: Rapid method for attenuating the alcohol dependency syndrome
INVENTOR(S): Lotsof, Howard S., Staten Island, NY, United States
PATENT ASSIGNEE(S): NDA International, Inc., Staten Island, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4857523		19890815	
APPLICATION INFO.:	US 1988-221030		19880718	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Friedman, Stanley J.
LEGAL REPRESENTATIVE: Miskin, Howard C.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 326
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 90 OF 97 USPATFULL on STN
ACCESSION NUMBER: 86:26606 USPATFULL
TITLE: Rapid method for interrupting the cocaine and amphetamine abuse syndrome
INVENTOR(S): Lotsof, Howard S., 330 Stanley Ave., Staten Island, NY, United States 10301

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4587243		19860506	
APPLICATION INFO.:	US 1985-754836		19850715	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Friedman, Stanley J.
LEGAL REPRESENTATIVE: Miskin, Howard C.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 289
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 91 OF 97 USPATFULL on STN
ACCESSION NUMBER: 85:8978 USPATFULL
TITLE: Rapid method for interrupting the narcotic addiction syndrome
INVENTOR(S): Lotsof, Howard S., 330 Stanley Ave., Staten Island, NY, United States 10301

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4499096		19850212	
APPLICATION INFO.:	US 1983-553138		19831118	(6)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Friedman, Stanley J.
LEGAL REPRESENTATIVE: Miskin, Howard C.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 302
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs 1-15

L3 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:836575 CAPLUS
DOCUMENT NUMBER: 139:341734
TITLE: Compositions of α3β4 nicotinic receptor antagonists and opioid agonist analgesics for pain relieving and diarrhea
INVENTOR(S): Simon, David Lew
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003199439	A1	20031023	US 2002-127359	20020422
US 2003199496	A1	20031023	US 2002-186402	20020701
WO 2003088918	A2	20031030	WO 2003-US12333	20030422
WO 2003088918	A3	20040916		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-127359 A2 20020422
US 2002-186402 A 20020701

AB Disclosed is a pharmaceutical composition comprising an opioid agonist analgesic and an α3β4 nicotinic receptor antagonist effective to sep. the brain-derived wanting of the opioid from the analgesic or anti-diarrhea effect of the opioid agonist. For example, morphine was formulated with 18-methoxy coronaridine for pain relief.

L3 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:757622 CAPLUS
DOCUMENT NUMBER: 136:111979
TITLE: Modulation of the effects of rewarding drugs by ibogaine
AUTHOR(S): Parker, Linda A.; Siegel, Shepard
CORPORATE SOURCE: Department of Psychology, Wilfrid Laurier University, Waterloo, ON, N2L 3C5, Can.
SOURCE: Alkaloids (Academic Press) (2001), 56(Ibogaine), 211-225
CODEN: ALKAAR; ISSN: 0099-9598
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review describes evidence that **ibogaine** modulates the drug effects in animals. Exptl. results show that **ibogaine** modulates various opiate effects in rats, as well as potentiates opiate-induced **analgesia** and lethality and interferes with morphine tolerance. When assessed in self-administration and in place preference learning, **ibogaine** modulates the rewarding properties of stimulants and interferes with the rewarding properties of morphine. (c) 2001 Academic Press.

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:184122 CAPLUS

DOCUMENT NUMBER: 130:205166
TITLE: **Noribogaine** in the treatment of **pain** and drug addiction
INVENTOR(S): Mash, Deborah C.
PATENT ASSIGNEE(S): Novoneuron, Inc., USA
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911250	A2	19990311	WO 1998-US18284	19980903
WO 9911250	A3	19990805		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2302754	AA	19990311	CA 1998-2302754	19980903
AU 9892174	A1	19990322	AU 1998-92174	19980903
AU 754088	B2	20021107		
EP 1009407	A2	20000621	EP 1998-944698	19980903
EP 1009407	B1	20040428		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
EP 1327447	A1	20030716	EP 2003-75683	19980903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
AT 265213	E	20040515	AT 1998-944698	19980903

PRIORITY APPLN. INFO.:

US 1997-57921P	P	19970904
EP 1998-944698	A3	19980903
WO 1998-US18284	W	19980903

AB The present invention is directed to methods of treating patients for **pain** by administering **noribogaine**. **Noribogaine** may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the **noribogaine** treatment should be supplemented with the administration of an opioid antagonist such as naloxone.

L3 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:656503 CAPLUS
DOCUMENT NUMBER: 129:270563
TITLE: Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice
AUTHOR(S): Sharma, Shyam Sunder; Bhargava, Hemendra N.
CORPORATE SOURCE: Department Pharmaceutics Pharmacodynamics (M/C 865), Health Sciences Center, University Illinois, Chicago, IL, 60612, USA
SOURCE: Pharmacology (1998), 57(5), 229-232
CODEN: PHMGBN; ISSN: 0031-7012
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effects of ibogaine, an alkaloid isolated form the bark of the African shrub, Tabernathe iboga, and noribogaine, a metabolite of ibogaine, on morphine antinociception were determined in male Swiss-Webster mice. Mice were rendered tolerant to morphine by implanting them with a pellet containing 25 mg of morphine base for 3 days. Placebo pellet-implanted mice served as controls. The antinociception of morphine (10 mg/kg, s.c.) was determined alone or in combination with an appropriate dose of ibogaine or noribogaine. Tolerance to morphine developed as a result of morphine pellet implantation as evidenced by decreased antinociceptive response to morphine. Both ibogaine and noribogaine dose-dependently enhanced morphine antinociception in morphine-tolerant but not in morphine-naive

mice. It is concluded that ibogaine and noribogaine enhance morphine antinociception in morphine-tolerant mice.

L3 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:478266 CAPLUS
DOCUMENT NUMBER: 129:225605
TITLE: Gender differences in kappa-opioid modulation of cocaine-induced behavior and NMDA-evoked dopamine release
AUTHOR(S): Sershen, Henry; Hashim, Audrey; Lajtha, Abel
CORPORATE SOURCE: Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, 10962, USA
SOURCE: Brain Research (1998), 801(1-2), 67-71
CODEN: BRREAP; ISSN: 0006-8993
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB It has been reported that kappa-opioids produce greater **analgesia** in women than in men. Sex differences are also apparent in drug-induced behaviors. Repeated administration of cocaine (25 mg/kg) produced a greater locomotor and sensitization response in C57BL/6By female mice. It was examined whether the increased sensitization in females to repeated cocaine administration was related to differences in kappa-opioid responses. The effects of the kappa agonist U62066 (spiradoline mesylate) on cocaine-induced locomotor stimulation in vivo and NMDA-mediated dopamine release in vitro were measured. In male, but not female mice, U62066 (1 mg/kg) given 30 min before cocaine potentiated the locomotor stimulation of an acute cocaine administration. U-62066 did not affect the development of locomotor sensitization with repeated cocaine administration (25 mg/kg s.c., once daily for 3 days), and a further enhanced response was not seen on days 2 and 3. It was then examined whether dopamine release, measured in vitro, plays a role in sex dependent differences in kappa-opioid- or NMDA-modulated dopaminergic function. In tissue perfusion studies, the in vitro NMDA (25 μM)-evoked release of labeled dopamine from striatum was lower in females (fractional release=5.4±0.4 and 4.0±0.4 in male and female mouse striatum). U62066 (1 μM) and **ibogaine** (1 μM), an indole alkaloid claimed to be useful in the treatment of drug addiction that acts in part at the kappa-opioid receptor, both reduced the NMDA (25 μM)-evoked release of dopamine. Inhibition of the release was significantly greater in tissue from male mice. Prior in vivo cocaine administration did not alter the NMDA-evoked dopamine release. Our studies indicate that kappa-opioid and NMDA receptor activity show differences between female and male mice that may account for differences in cocaine-induced behaviors, but do not exclude the role of other heteroceptors modulating dopamine release.
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:679297 CAPLUS
DOCUMENT NUMBER: 128:266
TITLE: Effects of noribogaine on the development of tolerance to antinociceptive action of morphine in mice
AUTHOR(S): Bhargava, Hemendra N.; Cao, Ying-Jun
CORPORATE SOURCE: Department of Pharmaceutics and Pharmacodynamics (m/c 865), The University of Illinois at Chicago, Health Sciences Center, 833 South Wood Street, Chicago, IL, 60612, USA
SOURCE: Brain Research (1997), 771(2), 343-346
CODEN: BRREAP; ISSN: 0006-8993
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The effects of noribogaine, a metabolite of ibogaine, on the development of tolerance to the antinociception action of morphine was determined in male Swiss-Webster mice. Ibogaine is an alkaloid isolated from the bark of the African shrub, Tabernanthe iboga. Morphine tolerance in mice was

developed by two different methods. Mice were rendered tolerant to morphine either by s.c. implantation of a pellet containing 25 mg morphine free base for 4 days or by injecting morphine (20 mg/kg, s.c.) twice a day for 4 days. Placebo pellet implanted mice or vehicle injected mice served as controls. To determine the effect of i.p. administered noribogaine on tolerance development, the drug was injected in the appropriate dose twice a day. In pellet implanted mice, a dose of 20 mg/kg of noribogaine attenuated the tolerance to morphine whereas lower doses had no effect. Similarly, in mice given multiple injections of morphine, noribogaine attenuated tolerance development at 20 and 40 mg/kg doses. Previous studies from this laboratory had shown that ibogaine at 40 and 80 mg/kg doses inhibited tolerance to morphine. Because noribogaine could attenuate morphine tolerance at lower doses than ibogaine, it is concluded that the attenuating effect of ibogaine on morphine tolerance may be mediated by its conversion to noribogaine, a more active metabolite.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:156629 CAPLUS

DOCUMENT NUMBER: 126:258958

TITLE: Effects of ibogaine on the development of tolerance to antinociceptive action of μ-, δ- and κ-opioid receptor agonists in mice

AUTHOR(S): Cao, Ying-Jun; Bhargava, Hemendra N.

CORPORATE SOURCE: Department of Pharmaceutics and Pharmacodynamics (m/c 865), The University of Illinois at Chicago, Health Sciences Center, 833 South Wood Street, Chicago, USA

SOURCE: Brain Research (1997), 752(1,2), 250-254
CODEN: BRREAP; ISSN: 0006-8993

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effects of ibogaine, an alkaloid isolated from the bark of the African shrub, Tabernanthe iboga, on the development of tolerance to the antinociception action of morphine, U-50,488H and [D-Pen2,D-Pen5]enkephalin (DPDPE), which are μ-, κ- and δ-opioid receptor agonists, resp., were determined in male Swiss-Webster mice. Mice were rendered tolerant to opioid receptor agonists by injecting morphine (20 mg/kg, s.c.), U-50,488H (25 mg/kg, i.p.) or DPDPE (20 μg/mouse, i.c.v.) twice a day for 4 days. Ibogaine (20, 40 or 80 mg/kg, i.p.) given twice a day for 4 days did not alter the tail-flick latency. Ibogaine (40 or 80 mg/kg, i.p.) injected 10 min before each injection of morphine inhibited the development of tolerance to the antinociceptive action of morphine, however, the lower dose of ibogaine (20 mg/kg, i.p.) was ineffective. Ibogaine (20, 40 or 80 mg/kg, i.p.) given prior to the injection of U-50,488H or DPDPE did not modify the development of tolerance to their antinociceptive action. It is concluded that ibogaine inhibits selectively the development of tolerance to the antinociceptive action of μ- but not κ- or δ-opioid receptor agonists in mice.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:156627 CAPLUS

DOCUMENT NUMBER: 126:246705

TITLE: Effects of ibogaine and noribogaine on the antinociceptive action of μ-, δ- and κ-opioid receptor agonists in mice

AUTHOR(S): Bhargava, Hemendra N.; Cao, Ying-Jun; Zhao, Guo-Min

CORPORATE SOURCE: Department of Pharmaceutics and Pharmacodynamics (M/C 865), The University of Illinois at Chicago, Health Sciences Center, 833 South Wood Street, Chicago, USA

SOURCE: Brain Research (1997), 752(1,2), 234-238
CODEN: BRREAP; ISSN: 0006-8993

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Ibogaine, an alkaloid isolated from the bark of the African shrub, Tabernanthe iboga, has been claimed to decrease the self-administration of drugs of abuse like morphine, cocaine and alc. To determine whether these effects are mediated via opioid receptor systems, the effects of ibogaine and its metabolite, noribogaine on the antinociceptive actions of morphine, U-50,488H and [D-Pen2,D-Pen5]enkephalin (DPDPE) which are μ- κ- and δ-opioid receptor agonists, resp., were determined in male Swiss-Webster mice. Administration of morphine (7 or 10 mg/kg, s.c.), U-50,488H (15 or 25 mg/kg, i.p.) or DPDPE (10 μg/mouse, i.c.v.) produced antinociception in mice as measured by the tail-flick test. Ibogaine (10, 20 or 40 mg/kg, i.p.) by itself did not alter the tail-flick latency. The same doses of ibogaine injected 10 min before the opioid drugs did not modify the antinociceptive actions of morphine, U-50,488H or DPDPE. Ibogaine administered 4 h or 24 h prior to morphine injection did not modify the antinociceptive action of the latter. A dose of 40 mg/kg (i.p.) of noribogaine enhanced the antinociceptive activity of morphine (10 mg/kg, s.c.). Similarly, the doses of 40 and 80 mg/kg of noribogaine enhanced the antinociception produced by a smaller dose of morphine (5 mg/kg, s.c.). However, antinociception induced by U-50,488H and DPDPE was not modified by noribogaine (10-40 mg/kg). It is concluded that ibogaine, which has been suggested to decrease the self-administration of cocaine and opiates like heroin in humans, does not produce such an action by interacting directly with multiple opioid receptors. However, the metabolite of ibogaine enhances the antinociception of morphine but not of U-50,488H or DPDPE. Thus, in vivo evidence has been provided for the possible interaction of ibogaine with μ-opioid receptor following its metabolism to noribogaine.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:692751 CAPLUS

DOCUMENT NUMBER: 126:26668

TITLE: Modulation of morphine-induced antinociception by ibogaine and noribogaine

AUTHOR(S): Bagal, A. A.; Hough, L. B.; Nalwalk, J. W.; Glick, S. D.

CORPORATE SOURCE: Department of Pharmacology and Neuroscience, A-136, Albany Medical College, 47 New Scotland Ave., Albany, NY, 12208, USA

SOURCE: Brain Research (1996), 741(1,2), 258-262
CODEN: BRREAP; ISSN: 0006-8993

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The potential modulation of morphine antinociception by the putative anti-addictive agent ibogaine and its active metabolite (noribogaine) was investigated in rats with the radiant heat tail-flick test. Ibogaine pretreatment (40 mg/kg, i.p., 19 h) significantly decreased morphine (4 mg/kg, s.c.) antinociception, with no effects in the absence of morphine. However, co-administration of ibogaine (1-40 mg/kg, i.p.) and morphine (4 mg/kg, s.c.) exhibited a dose-dependent enhancement of morphine antinociception. Co-administration of noribogaine (40 mg/kg, i.p.) and morphine also resulted in an increase in morphine antinociception, while noribogaine pretreatment (19 h) had no effect on morphine antinociception. The results show that ibogaine acutely potentiates morphine antinociception and that noribogaine could be the active metabolite responsible for this effect. However, the inhibitory effects of a 19 h ibogaine pretreatment, which resemble ibogaine-induced inhibition of morphine's stimulant properties, cannot be accounted for by noribogaine.

L3 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:587657 CAPLUS

DOCUMENT NUMBER: 125:238454

TITLE: Effect of **ibogaine** on the development of tolerance to the **analgesic** effect of morphine

AUTHOR(S): Siegel, Shepard; Kim, Joseph A.; Weise-Kelly, Lorraine; Parker, Linda A.
CORPORATE SOURCE: Department Psychology, McMaster University, Hamilton, ON, L8S 4K1, Can.
SOURCE: Experimental and Clinical Psychopharmacology (1996), 4(3), 258-263
CODEN: ECLPES; ISSN: 1064-1297
PUBLISHER: American Psychological Association
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The results of 3 expts. demonstrated that (a) 20 mg/kg **ibogaine** (but not 10 mg/kg), administered 30 min before morphine, attenuates the development of tolerance to the **analgesic** effect of morphine in rats; (b) this 20 mg/kg dose of **ibogaine**, if administered 5 h before morphine, has no effect on tolerance development; and (c) a high dose of **ibogaine** (40 mg/kg), administered 24 h before morphine, does not affect **analgesic** tolerance (despite reports that this dose of **ibogaine**, administered 1 day before morphine, modulates the neurochem. and reinforcing effect of the opiate. The findings are discussed in the context of suggestions that **ibogaine** be evaluated as a treatment for opiate dependence, and recent research indicating that **ibogaine** is an N-methyl-D-aspartate antagonist.

L3 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:871276 CAPLUS
DOCUMENT NUMBER: 123:275915
TITLE: High affinity ibogaine binding to a mu opioid agonist site
AUTHOR(S): Codd, Ellen E.
CORPORATE SOURCE: Drug Discovery, R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477-0776, USA
SOURCE: Life Sciences (1995), 57(20), PL315-PL320
CODEN: LIFSAK; ISSN: 0024-3205
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The naturally occurring indole alkaloid **ibogaine** is of interest because of its reported ability to block drug-seeking behavior for extended periods. The compound also potentiates morphine-induced **analgesia** in mice and reduces certain naltrexone-precipitated withdrawal signs in morphine-dependent rats. Although these results might suggest **ibogaine** interaction with opioid receptors, previous receptor binding studies (Brain Res. 571:242-247, 1980) found that **ibogaine** had a Ki value of only 2 μM for the kappa opioid receptor and was virtually inactive in blocking mu and delta receptor binding (Ki > 100 μM). The present investigation of **ibogaine** interaction with the mu opioid receptor from mouse forebrain labeled with [3H]-naloxone, however, yielded significantly more potent mu opioid Ki values. LIGAND anal. indicated that the data were best fit by a two site binding model, with Ki values of about 130 nM and 4 μM, reflecting **ibogaine** recognition of different agonist affinity states of the receptor. Inclusion of 100 mM NaCl in the assay to induce the agonist low affinity state of the receptor, reduced **ibogaine**'s inhibition of [3H]-naloxone binding. These results suggest that **ibogaine** is an agonist at the mu opioid receptor with a Ki value of about 130 nM, potentially explaining **ibogaine**'s antinociceptive effects as well as its reported reduction of opioid withdrawal symptoms and attenuation of drug seeking behavior.

L3 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:749395 CAPLUS
DOCUMENT NUMBER: 123:199189
TITLE: Medicinal chemical studies of anti-inflammatory and analgesic natural products
AUTHOR(S): Shen, Tsung-Ying
CORPORATE SOURCE: Chem. Dep., Univ. Virginia, Charlottesville, VA, 22903, USA
SOURCE: Journal of the Chinese Chemical Society (Taipei)

(1995), 42(4), 617-21
CODEN: JCCTAC; ISSN: 0009-4536
PUBLISHER: Chinese Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A symposium, following the discovery of salicylates and its conversion to aspirin, natural products research has provided many promising leads for further modification as anti-inflammatory and **analgesic** agents. Recent studies have focused on biosynthesis inhibitors of eicosanoids and receptor antagonists of the platelet activating factor, including a new class of dual functional inhibitors derived from neolignans. The highly potent **analgesic** alkaloid epibatidine from the frog skin has been synthesized and recharacterized as a very strong acetylcholine nicotinic receptor agonist. Some novel epibatidine analogs have shown promise as potential central nervous system drugs and research probes for clarifying the anti-addictive property of the African alkaloid **ibogaine**.

L3 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1973:97857 CAPLUS
DOCUMENT NUMBER: 78:97857
TITLE: Acyl derivatives of 10-methoxyibogamine
INVENTOR(S): Epstein, Joseph William; Goldman, Leon
PATENT ASSIGNEE(S): American Cyanamid Co.
SOURCE: U.S., 3 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3715361	A	19730206	US 1971-187895	19711008
PRIORITY APPLN. INFO.:			US 1971-187895 A	19711008

GI For diagram(s), see printed CA Issue.

AB The title compds. (I, R, = H, CHO; R1 = Ac, CHO, H; R2 = Ac, H) were prepared by acylation of **ibogaine** (I, R = R1 = R2 = H) with mixts. of DMF-POCl3, Me2N(:CHCl)Cl-CHCl3, s-triazine-CF3CO2H, or AcOH-Ac2O-BF3. I showed **analgetic** and antiinflammatory activity in rats with doses of 50 to 250 mg/kg.

not the same compound

L3 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1958:27271 CAPLUS
DOCUMENT NUMBER: 52:27271
ORIGINAL REFERENCE NO.: 52:4935h-i
TITLE: Analgesic compositions
INVENTOR(S): Schneider, Jurg A.
PATENT ASSIGNEE(S): Ciba Pharmaceutical Products, Inc.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2817623		19571224	US	

AB Tabernanthine and **ibogaine** potentiate **analgesics**, e.g., morphine, codeine, dihydromorphinone, dihydromethylmorphinone, pantopon, ethylmorphine, ketobemidon, meperidine, dihydrocodeinone, dihydromorphine, dihydrodeoxymorphine, dihydrodeoxycodeine, DL-3-methoxy-N-methylmorphinan, and DL-3-hydroxy-N-methylmorphinan. The ratio of the indole alkaloid to the **analgesic** component is 0.5-20:1. The ingredients may be incorporated in injectable solns., tablets, or capsules.

L3 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1956:91229 CAPLUS

DOCUMENT NUMBER: 50:91229
ORIGINAL REFERENCE NO.: 50:17154b-d
TITLE: Potentiating action of **ibogaine** (Bogadin TM) on morphine **analgesia**
AUTHOR(S): Schneider, J. A.; McArthur, Marie
CORPORATE SOURCE: Ciba Inc., Summit, NJ
SOURCE: Experientia (1956), 12, 323-4
CODEN: EXPEAM; ISSN: 0014-4754
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In white mice ibogaine-HCl (I) has a marked potentiating effect on morphine (II), ketobemidone, codeine, and Demerol, but not on aminopyrine. The most effective combination with II was 3 mg. with 24 mg. I. The toxicity of I-II combinations is greater than for either alone; the L.D.50 for equal amts. appears to be about 70 mg. of each.